ARCHIVES

Von Eschenbach a “misguided choice” for FDA, House members write to HHS Secretary Leavitt. Conflicts inadequately addressed, they said.

This article is from The Cancer Letter archive.

Vol. 31 No. 37 | October 14, 2005

Download PDF Visit The Full Archive

Related Articles

RFP: Sole Source

May 12, 2000

ASCO Releases Guideline On Larynx Preservation

July 28, 2006

National Cancer Policy Board a Successful Experiment, NCI Says; Funding Extended

May 19, 2000

AGS-003 Immunotherapy Induces T Cell Responses in Phase II Trial

November 29, 2013

CPRIT Awards $107.2 Million Round of Grants

September 5, 2014

New Cyclotron Delivered To University of Maryland, Instigating D.C.-Area Proton Radiation Competition

June 20, 2014